Resource Library
Reflections on advancing life science so we can get new drugs to market faster.
Sort by:
Webinar: Useful Generalization is the Benchmark That Matters
Updated:
DODock and DOScore: Closing the Generalization Gap in Structure-Based Virtual Screening
Updated:
Deep Origin Introduces Novel Virtual Screening Architecture; Achieves 100-fold Hit Rate Jump on Challenging Target
Updated:
Overcoming the accuracy-generalization tradeoff in docking and scoring for prospective virtual screening
Updated:
Deep Origin's Computational Platform Rationalizes Results of Molecular Glue Compound That Potently Kills Diffuse Large B Cell Lymphoma Cells
Updated:
A bivalent molecular glue linking lysine acetyltransferases to oncogene-induced cell death
Updated:
Michael Antonov: From Virtual World Builder to Real-World Drug Designer
Updated:
Can AI Shrink the Drug Development Timelines for Endometriosis?
Updated:
Tim Foley Joins Deep Origin as Chief Commercial Officer
Updated:
Deep Origin Promotes Natalie Ma, PhD, to Chief Business Officer as Company Advances Computational Drug Discovery Platform
Updated:
Deep Origin Congratulates Isomorphic Labs on Catching Up
Updated:
Finding Promising Molecules and Biological Background With Balto
Updated:
We Built a 98% Accurate Full Molecule Data Extractor for PDFs, Now You Can Use It
Updated:
Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety
Updated:
We're Leading an Up to $31.7M ARPA-H Contract Award to Build In-Silico Models To Replace Animal Testing
Updated:
Accelerating Drug Discovery with Physics-Informed Machine Learning
Updated:
Deep Origin Partners with AccuKnox for Cloud Security
Updated:
Out-of-the-Box GenAI for Medicinal Chemistry
Updated:
A Blind Spot in Drug Discovery: Pocket Finding
Updated:
Ashot Papoyan Advances Biotech in US and Armenia
Updated:
Deep mutational scanning reveals EGFR mutations conferring resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945
Updated:
From Scientist to Startup Founder: Building the Virtual Cell for Drug Discovery
Updated:
Can AI Agents Design and Implement Drug Discovery Pipelines?
Updated:
Simulating Life & Accelerating Discovery: Deep Origin's Biotech Vision | Michael Antonov (Part 4/4)
Updated:
Debugging Aging: How a VR Pioneer is Revolutionizing Longevity | Michael Antonov (Part 3/4)
Updated:
Building Oculus: Innovation, Grit & the $2 Billion VR Revolution | Michael Antonov (Part 2/4)
Updated:
The Borrowed Computer That Built Oculus - An Unlikely Biotech Journey | Michael Antonov (Part 1/4)
Updated:
Practical and Accurate Free Energy Calculations using Neural Network Potentials
Updated:
Benchmarking and Development of AI-Based Agentic Systems for Autonomous Drug Discovery
Updated:
Deep Origin Challenge 2025
Updated:
Why Deep Origin Is Betting on Both Physics and AI for Drug Discovery (EP 132)
Updated:
Will Oculus Co-founder Be Able To Simulate Biology Next?
Updated:
Implications of Protein Dynamics for Design of PROTACs and Molecular Glues
Updated:
JPM ‘25 From the Trenches: AI in Biotech Gets Tactical
Updated:
How Biotech Will Shape Our Future on Mars and Beyond ft. Natalie Ma
Updated:
How to Best Build a (Useful) Virtual Cell?
Updated:
Simulating Life with AI: A New Era in Biology with Michael Antonov & Natalie Ma from Deep Origin
Updated:
Finally, a Useful AI Assistant for Drug Discovery: Meet Balto
Updated:
Deep Origin Launches First and Only Drug Discovery Assistant with Conversational AI Interface and Top Docking Technology
Updated:
Drug Discovery AI Hype and Reality: Three Scientists Go On a Hike
Updated:
Getting Your Life Science Data Ready For the AI Era
Updated:
Discovering Novel Synthetic Lethal Pairs With Large Scale Cellular Simulations
Updated:
Deep Origin's Balto AI Assistant offers bespoke drug discovery tools via a chat interface
Updated:
Addressing Drug Discovery Challenges with a Multiscale Molecular Modeling Pipeline
Updated:
AlphaFold 3: Exciting Advance yet Unresolved Major Issues Remain
Updated:
Getting Started with Computational Drug Discovery
Updated:
We Spill the Beans: Deep Origin's AI- and Physics-Based Models for Drug Discovery
Updated:
Where Docking and Virtual Screening Can Drop the Ball in Drug Discovery
Updated:
Docking and Virtual Screening in Drug Discovery: Finding the Right Hit
Updated:
Variant calling with NVIDIA Parabricks and GATK
Updated:
Deep Origin and BiosimAI join forces in merger to accelerate R&D
Updated:
From chaos to (some) order: The Life Science Software Landscape
Updated:
Formic Labs is now Deep Origin
Updated:
No resources found matching your criteria.